Natera, Inc. (NASDAQ:NTRA) Shares Acquired by Alberta Investment Management Corp

Alberta Investment Management Corp lifted its position in shares of Natera, Inc. (NASDAQ:NTRA) by 62.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,199 shares of the medical research company’s stock after purchasing an additional 19,218 shares during the quarter. Alberta Investment Management Corp’s holdings in Natera were worth $7,099,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Price T Rowe Associates Inc. MD grew its stake in Natera by 134.9% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,742,428 shares of the medical research company’s stock valued at $1,067,327,000 after acquiring an additional 3,871,862 shares during the period. Geode Capital Management LLC grew its stake in Natera by 6.8% in the 4th quarter. Geode Capital Management LLC now owns 2,232,681 shares of the medical research company’s stock valued at $355,809,000 after acquiring an additional 142,201 shares during the period. Castle Hook Partners LP grew its stake in Natera by 7.2% in the 4th quarter. Castle Hook Partners LP now owns 1,222,578 shares of the medical research company’s stock valued at $193,534,000 after acquiring an additional 82,488 shares during the period. AQR Capital Management LLC grew its stake in Natera by 21.8% in the 4th quarter. AQR Capital Management LLC now owns 945,511 shares of the medical research company’s stock valued at $149,674,000 after acquiring an additional 169,148 shares during the period. Finally, ARK Investment Management LLC grew its stake in Natera by 6.2% in the 1st quarter. ARK Investment Management LLC now owns 943,094 shares of the medical research company’s stock valued at $133,363,000 after acquiring an additional 55,383 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Stock Up 0.7%

NASDAQ NTRA opened at $134.58 on Friday. Natera, Inc. has a 52 week low of $92.14 and a 52 week high of $183.00. The business’s fifty day simple moving average is $157.16 and its 200-day simple moving average is $155.88. The firm has a market cap of $18.38 billion, a PE ratio of -91.55 and a beta of 1.76.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.09. The business had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The company’s quarterly revenue was up 36.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.56) EPS. Research analysts expect that Natera, Inc. will post -1.49 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on NTRA shares. Barclays lifted their price target on shares of Natera from $160.00 to $190.00 and gave the company an “overweight” rating in a research note on Friday, May 9th. UBS Group raised their price objective on Natera from $211.00 to $218.00 and gave the company a “buy” rating in a report on Friday, May 9th. Wall Street Zen lowered Natera from a “hold” rating to a “sell” rating in a report on Saturday, May 17th. Evercore ISI upgraded Natera to a “strong-buy” rating and set a $170.00 price objective on the stock in a report on Monday, July 28th. Finally, Piper Sandler raised their price objective on Natera from $205.00 to $210.00 and gave the company an “overweight” rating in a report on Thursday, May 15th. One equities research analyst has rated the stock with a sell rating, fifteen have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $183.76.

Insiders Place Their Bets

In related news, insider Solomon Moshkevich sold 2,206 shares of the firm’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $139.81, for a total transaction of $308,420.86. Following the completion of the sale, the insider directly owned 126,059 shares of the company’s stock, valued at approximately $17,624,308.79. This trade represents a 1.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John Fesko sold 1,710 shares of the firm’s stock in a transaction dated Monday, July 28th. The stock was sold at an average price of $139.81, for a total value of $239,075.10. Following the sale, the insider directly owned 151,750 shares of the company’s stock, valued at $21,216,167.50. The trade was a 1.11% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 48,936 shares of company stock valued at $7,483,846 over the last 90 days. Company insiders own 7.60% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.